Computed tomography-guided cryoablation in treating adrenal metastases: a retrospective single-center study

PURPOSE To assess the effectiveness and safety of computed tomography (CT)-guided cryoablation for treating adrenal metastases (AMs). METHODS This study included 12 patients treated with 13 CT-guided cryoablation procedures for AMs between 2016 and 2020. Patients were selected based on specific criteria, including tumor size ≤5 cm and suitability for surgery. Procedures were performed by expert radiologists, with comprehensive monitoring for complications and regular post-treatment evaluations. RESULTS The primary technical success rate was 91.7%, with a secondary success rate of 100% following repeat procedures. Over an 8–24-month follow-up period, local tumor recurrence was observed in 16.7% of patients, and systemic progression occurred in five (41.6%) patients. The average overall survival duration was 26.4 ± 5.6 months. CONCLUSION CT-guided cryoablation is a feasible and effective treatment option for AMs, demonstrating high technical success rates and manageable complications. CLINICAL SIGNIFICANCE This study highlights CT-guided cryoablation as a promising treatment for AMs, offering a mini-mally invasive alternative to surgery with good local control and safety profile. Further research, including multi-center studies, is needed to confirm these findings.